PUK12 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND 10 MGVERSUS FESOTERODINE 4 MG AND 8 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE UK NHS

Nov 1, 2008, 00:00
10.1016/S1098-3015(10)67126-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)67126-4/fulltext
Title : PUK12 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND 10 MGVERSUS FESOTERODINE 4 MG AND 8 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE UK NHS
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67126-4&doi=10.1016/S1098-3015(10)67126-4
First page :
Section Title :
Open access? : No
Section Order : 961
Categories :
Tags :
Regions :
ViH Article Tags :